Market Overview:
The global severe acute respiratory syndrome (SARS) therapeutics market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing incidence of SARS, rising awareness about SARS and its treatment, and technological advancements in the field of SARS therapeutics. However, factors such as high cost of treatment and lack of reimbursement policies are likely to restrain the growth of this market during the forecast period. Based on type, the global severe acute respiratory syndrome (SARS) therapeutics market is segmented into CEL-1000, D-3252, FDX-000, INO-4500 LCA-60 Others. Based on application, it is segmented into hospital clinic research center. Geographically it has been analyzed across North America Latin America Europe Asia Pacific Middle East & Africa with further analysis done for key countries in each region.
Product Definition:
A severe, highly contagious respiratory illness caused by a previously unknown virus. Symptoms include fever, coughing, and difficulty breathing. SARS Therapeutics is important because it can help to treat the symptoms of this illness.
CEL-1000:
Celgene Corporation (U.S.), a major market player, has developed CEL-1000 in collaboration with BioCryst Pharmaceuticals for the treatment of SARS-CoV-2 infection. The drug is currently under phase III clinical trials and expected to be commercialized by 2017.
D-3252:
D-3252 is a selective inhibitor of voltage-gated L type calcium channels. It has potent anti-inflammatory and immunosuppressive properties, which may be useful in the treatment of SARS. Currently, it is under clinical investigation for this purpose and has been found to have nootropic effects when used in high doses over an extended period.
Application Insights:
Based on application, the global severe acute respiratory syndrome therapeutics market is segmented into hospital, clinic and research center. The hospital segment dominated the overall market in terms of revenue in 2017 owing to a large patient base with SARS-CoV-2 infection and increasing prevalence of severe SARS-CoV disease. In addition, this segment is expected to maintain its dominance over the forecast period due to ongoing clinical trials for potential new therapies.
The Clinic/research center segment is anticipated to witness lucrative growth during the forecast period due to increased R&D initiatives by public and private organizations at global level coupled with growing awareness about Severe Acute Respiratory Syndrome (SARS). For instance, Centers for Disease Control & Prevention (CDC) has recommended that people be tested frequently if they have been in contact with a person diagnosed with SARS-CoV since it can spread easily among humans.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a substantial number of players, high research activities, and favorable government initiatives. The region is expected to maintain its dominance throughout the forecast period due to factors such as increasing prevalence of SARS-CoV infection and rising healthcare expenditure. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing awareness about early diagnosis coupled with growing R&D activities by various companies for developing novel therapeutics for tackling this pandemic situation efficiently. Moreover, low manufacturing cost in countries like China & India coupled with easy availability of raw materials will drive regional growth further. In addition, increase in foreign investments are also contributing towards market development across emerging economies globally which include Indonesia & Malaysia among others (Table 1).
Growth Factors:
- Increasing incidence of respiratory diseases: The global incidence of respiratory diseases is increasing due to the changing lifestyle and environmental conditions. This is expected to drive the demand for SARS therapeutics products in the coming years.
- Growing awareness about SARS: There is a growing awareness among people about SARS and its treatment options. This is likely to boost the demand for SARS therapeutics products in the near future.
- Technological advancements: The technological advancements in the field of respiratory disease treatments are expected to fuel the growth of the global SARS therapeutics market in future years.
- Rising healthcare expenditure: The rising healthcare expenditure by governments and private players is anticipated to create lucrative opportunities for players operating in this market during forecast period 2017-2025 .
Scope Of The Report
Report Attributes
Report Details
Report Title
Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Research Report
By Type
CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others
By Application
Hospital, Clinic, Research Center
By Companies
CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC, Protein Sciences Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Report Segments:
The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market is segmented on the basis of:
Types
CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Research Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CEL-SCI Corporation
- GeneCure LLC
- Humabs BioMed SA
- Inovio Pharmaceuticals, Inc.
- Nanotherapeutics, Inc.
- Novavax, Inc.
- Phelix Therapeutics, LLC
- Protein Sciences Corporation
Highlights of The Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CEL-1000
- D-3252
- FDX-000
- INO-4500
- LCA-60
- Others
- By Application:
- Hospital
- Clinic
- Research Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
SARS therapeutics are medications used to treat SARS. These medications can help reduce the symptoms of SARS, such as fever, cough, and shortness of breath.
Some of the major companies in the severe acute respiratory syndrome (sars) therapeutics market are CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC, Protein Sciences Corporation.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size & Forecast, 2018-2028 4.5.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size and Y-o-Y Growth 4.5.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
5.2.1 CEL-1000
5.2.2 D-3252
5.2.3 FDX-000
5.2.4 INO-4500
5.2.5 LCA-60
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Research Center
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
9.6.1 CEL-1000
9.6.2 D-3252
9.6.3 FDX-000
9.6.4 INO-4500
9.6.5 LCA-60
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Research Center
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
10.6.1 CEL-1000
10.6.2 D-3252
10.6.3 FDX-000
10.6.4 INO-4500
10.6.5 LCA-60
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Research Center
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
11.6.1 CEL-1000
11.6.2 D-3252
11.6.3 FDX-000
11.6.4 INO-4500
11.6.5 LCA-60
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Research Center
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
12.6.1 CEL-1000
12.6.2 D-3252
12.6.3 FDX-000
12.6.4 INO-4500
12.6.5 LCA-60
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Research Center
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Severe Acute Respiratory Syndrome (SARS) Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Type
13.6.1 CEL-1000
13.6.2 D-3252
13.6.3 FDX-000
13.6.4 INO-4500
13.6.5 LCA-60
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Research Center
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market: Competitive Dashboard
14.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CEL-SCI Corporation
14.3.2 GeneCure LLC
14.3.3 Humabs BioMed SA
14.3.4 Inovio Pharmaceuticals, Inc.
14.3.5 Nanotherapeutics, Inc.
14.3.6 Novavax, Inc.
14.3.7 Phelix Therapeutics, LLC
14.3.8 Protein Sciences Corporation